Tgf-beta inhibition for immunodeficiency virus reactivation from latency, enhancement of immunodeficiency virus-specific responses and immunodeficiency virus cure
OwnerElena Martinelliinventor
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of treating immunodeficiency virus infection that include methods of treating latent immunodeficiency virus infection in immune cells using a TGF-β inhibitor with antiretroviral therapy.
Claims20
A method of treating a latent immunodeficiency virus infection in immune cells in a subject receiving antiretroviral therapy comprising administering a TGF-β inhibitor to the subject.
The method of claim 2, wherein the TGF-β inhibitor is galunisertib.
A method for activation of latent immunodeficiency virus in immune cells of a subject having an immunodeficiency virus infection treated with antiretroviral therapy comprising contacting the immune cells with a TGF-β inhibitor.
Dependencies are inferred from the claim text.